Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone858-320-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.07 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/28/2019 (Confirmed)
OptionableOptionable
Biocept (NASDAQ:BIOC) Frequently Asked Questions
What is Biocept's stock symbol?
Biocept trades on the NASDAQ under the ticker symbol "BIOC."
How were Biocept's earnings last quarter?
Biocept Inc (NASDAQ:BIOC) issued its earnings results on Tuesday, August, 14th. The medical research company reported ($2.70) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($3.30) by $0.60. The medical research company earned $0.82 million during the quarter, compared to the consensus estimate of $1.09 million. Biocept had a negative return on equity of 456.20% and a negative net margin of 715.42%. View Biocept's Earnings History.
When is Biocept's next earnings date?
What price target have analysts set for BIOC?
2 brokers have issued 1-year price targets for Biocept's shares. Their forecasts range from $1.00 to $1.00. On average, they anticipate Biocept's stock price to reach $1.00 in the next year. This suggests that the stock has a possible downside of 2.9%. View Analyst Price Targets for Biocept.
What is the consensus analysts' recommendation for Biocept?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biocept.
Has Biocept been receiving favorable news coverage?
Media headlines about BIOC stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Biocept earned a news sentiment score of -1.1 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.
Are investors shorting Biocept?
Biocept saw a decline in short interest in the month of February. As of February 15th, there was short interest totalling 466,391 shares, a decline of 76.2% from the January 31st total of 1,957,896 shares. Based on an average trading volume of 1,888,253 shares, the days-to-cover ratio is presently 0.2 days. Approximately 11.3% of the company's shares are sold short. View Biocept's Current Options Chain.
Who are some of Biocept's key competitors?
What other stocks do shareholders of Biocept own?
Who are Biocept's key executives?
Biocept's management team includes the folowing people:
- Mr. Michael W. Nall, CEO, Pres & Director (Age 56)
- Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations & Corp. Sec. (Age 61)
- Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer and Member of Scientific Advisory Board (Age 72)
- Dr. Soon Kap Hahn Ph.D., Founder
- Mr. Pavel Tsinberg, Director of Technology Devel.
Who are Biocept's major shareholders?
Biocept's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (4.86%) and Dimensional Fund Advisors LP (4.86%). View Institutional Ownership Trends for Biocept.
Which institutional investors are buying Biocept stock?
How do I buy shares of Biocept?
Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biocept's stock price today?
One share of BIOC stock can currently be purchased for approximately $1.03.
How big of a company is Biocept?
Biocept has a market capitalization of $2.34 million and generates $5.07 million in revenue each year. The medical research company earns $-21,610,000.00 in net income (profit) each year or ($23.72) on an earnings per share basis.
What is Biocept's official website?
How can I contact Biocept?
Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected]
MarketBeat Community Rating for Biocept (NASDAQ BIOC)
MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe BIOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
